New Delhi: In a move to bolster India’s fight against tuberculosis (TB), HaystackAnalytics has introduced ‘TB One,’ a Make-in-India solution designed to enhance TB diagnosis by enabling Next-Generation Sequencing (NGS) at any diagnostic lab or hospital. This all-in-one offering includes a pre-sequencing kit for Whole Genome Sequencing (WGS), access to ‘Omega TB’—HaystackAnalytics’ patented clinical reporting software—and on-demand access to 2GB of sequencing data.
The Omega TB software delivers a comprehensive clinical report covering resistance to 18 anti-TB drugs, along with mixed infections, non-tuberculous mycobacteria (NTM), and heteroresistance—all within a single, standardized report. By equipping healthcare providers with precise, data-driven insights, ‘TB One’ aims to improve TB management and strengthen India’s fight against the disease.
The Solution has been unveiled by Dr Anirvan Chatterjee, Co-founder & CEO, of HaystackAnalytics & Dr Rajendra Prasad at the Indian Council of Medical Research’s (ICMR) India Innovation Summit: Pioneering Solutions to End TB on March 19, 2025. With this solution genomics-based TB testing would become more accessible and scalable by enabling existing laboratories to upgrade to NGS testing for TB without significant infrastructure changes. This solution aligns seamlessly with HaystackAnalytics’ mission to make genomics accessible, applicable, and affordable, addressing a critical need to transform molecular diagnostic laboratories into advanced genomic facilities.Emphasizing on the potential of ‘TB One’ solution, Dr. Anirvan Chatterjee, Co-founder and CEO of HaystackAnalytics, said, “We are empowering existing molecular labs to perform high-precision genomic testing without requiring expensive infrastructure modifications. This cost-effective and scalable approach ensures greater accessibility to advanced TB diagnostics across India. Each TB One kit contains reagents to process 16 samples and requires prior extraction of TB DNA. It seamlessly integrates into existing molecular workflows, facilitating efficient TB genomic sequencing.”
Dr. Rajendra Prasad, a nationally acclaimed pulmonologist with over 51 years of experience in TB care and research, said, “Drug-resistant TB remains one of our toughest challenges, and faster, more precise diagnostics are the need of the hour. ‘TB One’ Solution can be a game-changer, bringing advanced genomic testing to everyday labs without major upgrades. By enabling comprehensive drug resistance profiling in a single test, it has the potential to help in TB care and save countless lives. This is a crucial step toward the journey of TB Mukt Bharat.”
